Delving into the Latest Updates on ProPharma Partners Ltd. with Synapse

概览

疾病领域	数量

免疫系统疾病	1
神经系统疾病	1

排名前五的药物类型	数量

干扰素	1

排名前五的靶点	数量

IFNAR(干扰素α/β受体复合体)	1

关联

1

项与 ProPharma Partners Ltd. 相关的药物

PEG-IFN-beta(Toray Industries, Inc.)

聚乙二醇干扰素β(Toray Industries, Inc.)

靶点

IFNAR

作用机制

IFNAR激动剂

在研机构

ProPharma Partners Ltd.

原研机构

Toray Industries, Inc.

在研适应症

多发性硬化症

非在研适应症

丙型肝炎

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与 ProPharma Partners Ltd. 相关的临床结果

登录后查看更多信息

0 项与 ProPharma Partners Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 ProPharma Partners Ltd. 相关的文献（医药）

Clinical and Translational Gastroenterology2区 · 医学

A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease

2区 · 医学

ArticleOA

作者: O'Herlihy, Eileen A. ; Jeffery, Ian B. ; Weinberg, John D. ; Gervais, Lisa ; Muhammed, Rafeeq ; Henderson, Paul ; Russell, Richard K. ; Kitson, Geoff ; Mullins, David P. ; Allen, Stephen ; Hansen, Richard ; Tzivinikos, Christos ; Wilson, David C. ; Sanderson, Ian R.

INTRODUCTION:Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We aimed to assess safety and tolerability in adolescents with Crohn's disease in remission.METHODS:Subjects who were 16–18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index <12.5) were recruited. Each active dose comprised ∼108.2±1.4 colony forming units of B. thetaiotaomicron (randomized 4:1 active:placebo). Part A was single dose. Part B involved 7.5 days twice daily dosing. Serial stools were analyzed for calprotectin, 16S rRNA sequencing, and B. thetaiotaomicron real-time polymerase chain reaction. Bloods were taken serially. Subjects reported adverse events and recorded temperature twice daily.RESULTS:Fifteen subjects were treated—8 in part A (75% men, median 17.1 years) and 10 in part B, including 3 from part A (80% men, median 17.1 years); all 18 completed. Seventy percent took concurrent immunosuppression. Reported compliance was >99% in part B. Two subjects reported adverse events deemed related—one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4–447] to 50.5 [5.3–572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota profiles, but diversity seemed to increase in treated subjects.DISCUSSION:Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were small, the safety profile seems good. Future studies should explore efficacy.

100 项与 ProPharma Partners Ltd. 相关的药物交易

登录后查看更多信息

100 项与 ProPharma Partners Ltd. 相关的转化医学

登录后查看更多信息